S-1

Alzheimer Disease Assessment Scale—Cognitive Subscale (ADAS-cog) 11-Item

Score rangeMemory and new learning 0 - 35

Word recall(mean number of words not recalled)

0 - 10

Orientation(one point for each incorrect response)

0 - 8

Word recognition(mean number of incorrect responses)

0 - 12

Remembering test instructions 0 - 5Language 0 - 25

Commands 0 - 5Spoken language ability 0 - 5Naming objects/fingers 0 - 5Word-finding difficulty 0 - 5Comprehension 0 - 5

Praxis 0 - 10Constructional praxis 0 - 5Ideational praxis 0 - 5

Total 0 - 70Increasing scores indicate worsening cognitive function.Rosen WG, et al. Am J Psychiatry. 1984;141:1356-1364.

S-2Treatment Difference at Wk 24 on ADAS-cog by CountryCore Study—ITT+RDO Population

Austria (N = 9)

Belgium (N = 21)

Canada (N = 41)

Germany (N = 63)

Spain (N = 59)

France (N = 63)

Great Britain (N = 48)

Italy (N = 118)

Netherlands (N = 18)

Norway (N = 7)

Portugal (N = 9)

Turkey (N = 45)

–10 0 10 20

LS mean difference (95% CI).

–20

–39.67

–29.92

46.92

Favor ExelonFavor placebo

S-3Duration of Nausea and Vomiting and Number of Events per PatientCore Study

Nausean (%)

Vomitingn (%)

Duration Events, N = 137 Events, N = 77

1 - 7 days 55 (40.1) 47 (61.0)

8 - 14 days 16 (11.7) 7 (9.1)

15 - 21 days 13 (9.5) 8 (10.4)

22 - 28 days 11 (8.0) 5 (6.5)

> 28 days 22 (16.1) 4 (5.2)

Continuing† 20 (14.6) 6 (7.8)

Number of events/patient Patients, N = 105 Patients, N = 60

1 81 (77.1) 49 (81.7)

2 19 (18.1) 8 (13.3)

3 2 (1.9) 1 (1.7)

> 3 3 (2.9) 2 (3.3)

† Events with no end dates recorded, which may or may not have resolvedby last study visit.

S-4Duration of Tremor and Number of These Events per PatientCore Study

Tremorn (%)

Duration Total events = 40

1 - 7 days 11 (27.5)

8 - 14 days 3 (7.5)

15 - 21 days 1 (2.5)

22 - 28 days 3 (7.5)

> 28 days 4 (10.0)

Continuing† 18 (45.0)

Number of events/patient Total patients = 37

1 34

2 3

3 0

> 3 0

1 episode: 34 patients; 2 episodes: 3 patients.† Events with no end dates recorded, which may or may not have resolved by last study visit.

S-5

AE of Tremor Over TimeCore and Extension Studies

Core Extension

Exelon n/N (%)

Placebo n/N (%)

Exe-Exelon n/N (%)

Plc-Exelon n/N (%)

Titration period, wk

Titration period, wk

0 - 4 7/362 (1.9) 3/179 (1.7) 24 - 28 0 1/123 (0.8)

> 4 - 8 9/343 (2.6) 0 > 28 - 32 3/207 (1.4) 6/119 (5.0)

> 8 - 12 15/324 (4.6) 1/165 (0.6) > 32 - 36 2/202 (1.0) 6/115 (5.2)

> 12 - 16 6/301 (2.0) 2/162 (1.2) > 36 - 40 2/195 (1.0) 2/107 (1.9)

Maintenanceperiod, wk

Maintenanceperiod, wk

> 16 - 20 2/281 (0.7) 1/158 (0.6) > 40 - 48 1/191 (0.5) 1/102 (1.0)

> 20 - 24 1/271 (0.4) 0

Patients are counted more than once if event continues through multiple periods.

S-6

Change on ADAS-cog Sub-items at Wk 24Core Study—OC Population

Mean ± SD

Exelon (N = 290) Placebo (N = 159)

ADAS-cog sub-item NChange at

Wk 24 NChange at

Wk 24 p value†

Item 1: word recall 255 0.5 ± 1.3 139 0.1 ± 1.3 0.014*Item 2: commands 258 0.3 ± 1.2 141 0.0 ± 1.3 0.023*Item 3: constructional praxis 249 0.2 ± 1.0 135 –0.1 ± 1.1 0.095Item 4: naming objects/fingers 258 0.1 ± 0.8 142 –0.1 ± 0.9 0.037*Item 5: ideational praxis 245 0.4 ± 1.5 134 –0.1 ± 1.3 < 0.001*Item 6: orientation 259 0.4 ± 1.8 143 –0.1 ± 1.7 0.060Item 7: word recognition 249 0.5 ± 3.3 137 –0.2 ± 3.6 0.106Item 8: remembering test instructions 256 0.2 ± 1.3 141 –0.1 ± 1.2 0.013*Item 9: spoken language ability 259 0.1 ± 1.2 142 –0.3 ± 1.0 0.032*Item 10: word finding difficulty 258 0.1 ± 1.0 142 0.0 ± 1.0 0.421Item 11: comprehension 259 0.2 ± 1.0 142 –0.2 ± 1.0 0.012*

*p < 0.05† p value based on van Elteren test blocking for country.

S-7

Major Protocol ViolationsCore Study

Exelon Placebo Total

Protocol violationN = 362n (%)

N = 179n (%)

N = 541n (%)

≥ 1 protocol violation 82 (22.7) 33 (18.4) 115 (21.3)

MMSE score < 10 or > 24 6 (1.7) 3 (1.7) 9 (1.7)

Date diagnosis PD > date of first symptoms of PDD –2 yr

14 (3.9) 3 (1.7) 17 (3.1)

Increased dose or newly introduced psychotropic/ dopaminergic medication

39 (10.8) 18 (10.1) 57 (10.5)

S-8Dopaminergic Agents—Dose Increase After Start of Study DrugCore Study

ExelonN = 362n (%)

PlaceboN = 179n (%)

Dopa and dopa derivatives 20 (5.5) 8 (4.5)

Dopamine agonists 3 (0.8) 1 (0.6)

Other dopaminergic agents 2 (0.6) 0

Doses were required to remain unchanged unless clinically indicated.